ArticleJournal of thoracic disease2026
Diagnosing lung cancer invading the pulmonary artery using ultra-low-dose CT pulmonary angiography: a feasibility study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Computed tomography pulmonary angiography (CTPA) is widely used for evaluating pulmonary artery invasion (PAI) in lung cancer, but conventional protocols involve relatively high radiation dose and contrast medium usage. The feasibility of a 60-kVp "triple-low" protocol combining low tube voltage, reduced contrast volume, and reduced injection rate in preserving image quality and diagnostic performance remains to be determined. Therefore, this study aimed to evaluate the feasibility of a 60-kVp "triple-low" CTPA protocol for assessing pulmonary artery invasion in patients with lung cancer. Methods: In this prospective randomized study, 90 patients were assigned to routine dose (RD) CTPA (120 kVp, 50 mL, 4.5 mL/s; n=45) or ultra-low-dose (ULD) CTPA (60 kVp, 35 mL, 3.5 mL/s; n=45). Two senior thoracic radiologists established the reference standard by consensus after reviewing available pathological, imaging, and clinical records. Subjective image quality was evaluated using a 5-point Likert scale across multiple parameters, including enhancement homogeneity and vascular sharpness. Radiation dose was recorded, and the signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were measured at the main, right, and left pulmonary arteries. Two additional readers independently assessed PAI; receiver operating characteristic (ROC) analysis against the reference standard yielded the area under the ROC curve (AUC), sensitivity, specificity, and accuracy. Results: ULD reduced effective dose (ED) from 3.59 to 0.72 mSv (~80%). Subjective scores were comparable between protocols for enhancement homogeneity, vascular sharpness, and diagnostic confidence (all P>0.05). SNR and CNR were similar overall, with a small decrease at the left pulmonary artery in the ULD group. Diagnostic performance for PAI was comparable between ULD and RD for both readers (reader 1: AUC 0.936 Conclusions: A 60-kVp triple-low CTPA protocol achieved ~80% dose reduction while maintaining image quality and diagnostic accuracy for evaluating PAI, supporting clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.